1. Home
  2. PZG vs IMMX Comparison

PZG vs IMMX Comparison

Compare PZG & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paramount Gold Nevada Corp.

PZG

Paramount Gold Nevada Corp.

HOLD

Current Price

$1.12

Market Cap

94.8M

ML Signal

HOLD

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

HOLD

Current Price

$4.83

Market Cap

82.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PZG
IMMX
Founded
1992
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Medicinal Chemicals and Botanical Products
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.8M
82.6M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
PZG
IMMX
Price
$1.12
$4.83
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
687.6K
613.1K
Earning Date
11-14-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$1.34
52 Week High
$1.41
$5.05

Technical Indicators

Market Signals
Indicator
PZG
IMMX
Relative Strength Index (RSI) 44.69 69.20
Support Level $1.18 $3.78
Resistance Level $1.26 $4.48
Average True Range (ATR) 0.08 0.44
MACD -0.01 0.00
Stochastic Oscillator 24.00 84.23

Price Performance

Historical Comparison
PZG
IMMX

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold, frost project, other non-material, and others.

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Share on Social Networks: